spironolactone has been researched along with Pneumonia, Viral in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cadegiani, FA | 2 |
| Liaudet, L | 1 |
| Szabo, C | 1 |
| Goren, A | 1 |
| Wambier, CG | 1 |
| Mareev, VY | 1 |
| Orlova, YA | 1 |
| Pavlikova, EP | 1 |
| Matskeplishvili, ST | 1 |
| Akopyan, ZA | 1 |
| Plisyk, AG | 1 |
| Seredenina, EM | 1 |
| Asratyan, DA | 1 |
| Potapenko, AV | 1 |
| Malakhov, PS | 1 |
| Samokhodskaya, LM | 1 |
| Mershina, EA | 1 |
| Sinitsyn, VE | 1 |
| Bulanova, MM | 1 |
| Fuks, AA | 1 |
| Mareev, YV | 1 |
| Begrambekova, YL | 1 |
| Kamalov, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for spironolactone and Pneumonia, Viral
| Article | Year |
|---|---|
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavi | 2020 |
Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
Topics: Coronavirus Infections; COVID-19; Humans; Mineralocorticoid Receptor Antagonists; Pandemics; Pneumon | 2020 |
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Topics: Androgen Antagonists; Androgens; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhi | 2020 |
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronŠ°virUs Infection requiring hospiTalization (BISCUIT)"].
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalizat | 2020 |